Shopping Cart
- Remove All
- Your shopping cart is currently empty
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | In Stock | |
5 mg | $95 | In Stock | |
10 mg | $139 | In Stock | |
25 mg | $233 | In Stock | |
50 mg | $349 | In Stock | |
100 mg | $516 | In Stock | |
500 mg | $1,090 | In Stock | |
1 mL x 10 mM (in DMSO) | $88 | In Stock |
Description | CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity. |
Targets&IC50 | CDK8:51.9 nM |
In vitro | CDK8-IN-13 (compound 43 ; 1, 2.5, 5, 10 µM ; 12 h) decreased p-STAT1 S727 and p-STAT5 S726 expression in HCT-116 cells in a dose-dependent manner.[1] CDK8-IN-13 (0, 1, 5, 10 µM ; 48 h) induced apoptosis in a dose-dependent manner.[1] |
In vivo | CDK8-IN-13 (40, 80 mg/kg ; orally ; for 15 days) inhibits tumor growth in a dose-dependent manner in mice.[1] |
Molecular Weight | 237.26 |
Formula | C14H11N3O |
Cas No. | 918523-75-8 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 112.5 mg/mL (474.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.